INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 48 filers reported holding INOZYME PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,257,500 | -1.8% | 5,537,500 | +30.3% | 0.05% | +3.9% |
| Q2 2023 | $23,672,500 | -3.1% | 4,250,000 | -0.4% | 0.05% | -7.3% |
| Q1 2023 | $24,439,241 | +650.8% | 4,265,138 | +37.6% | 0.06% | +587.5% |
| Q4 2022 | $3,255,145 | -53.2% | 3,100,138 | +19.4% | 0.01% | -52.9% |
| Q3 2022 | $6,959,000 | -42.7% | 2,596,672 | +2.0% | 0.02% | -39.3% |
| Q2 2022 | $12,148,000 | +70.0% | 2,546,672 | +45.8% | 0.03% | +100.0% |
| Q1 2022 | $7,144,000 | -34.5% | 1,746,672 | +9.2% | 0.01% | -30.0% |
| Q4 2021 | $10,905,000 | -35.9% | 1,599,028 | +8.9% | 0.02% | -41.2% |
| Q3 2021 | $17,012,000 | -22.5% | 1,467,828 | +13.9% | 0.03% | -20.9% |
| Q2 2021 | $21,959,000 | +1.8% | 1,288,672 | +18.3% | 0.04% | -2.3% |
| Q1 2021 | $21,576,000 | +16.6% | 1,089,672 | +21.5% | 0.04% | +10.0% |
| Q4 2020 | $18,507,000 | -12.0% | 896,672 | +12.1% | 0.04% | -24.5% |
| Q3 2020 | $21,032,000 | – | 800,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |